RxDoctor Payments Data

Erica Deangelo, PA

Physician Assistant · Redondo Beach, CANPI 1134694946

Payments from drug & device makers

$4,846in general payments, 2019–2025

Across 171 payments — averaging $28.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$843
  • Dermavant Sciences, Inc.$704
  • AbbVie$671
  • Sanofi$583
  • Arcutis Biotherapeutics, Inc.$359
  • Novartis$338
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$4,71697%
  • Education$1303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,846 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$16,060
Medicare patients
62
Services billed
186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab27$110,462
OpzeluraRuxolitinib Phosphate15$45,412
Tacrolimus149$36,387
VtamaTapinarof11$14,667
Calcipotriene49$11,073
Fluocinonide97$9,014
MupirocinMupirocin Calcium26$4,719
Metronidazole61$4,183
Clobetasol Propionate83$3,414
Pimecrolimus12$3,131
Tretinoin38$2,725
Clindamycin Phosphate39$2,486
Alclometasone Dipropionate30$2,011
Ketoconazole116$1,941
Gentamicin Sulfate40$1,744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationOpzelura$843$45,41215 claims
Dermavant Sciences, Inc.Vtama$704$14,66711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Redondo Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →